Summary
For Year 2026-27, Remus Pharmaceuticals reports the following shareholding: Total Promoters at 70.95%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 5.28%, Domestic Institutional Investors at 0.83%, and Retail at 22.94%. This breakdown provides a quick snapshot of ownership distribution for Remus Pharmaceuticals in 2026-27.
Remus Pharmaceuticals FAQs
As of 04-2026, the promoter shareholding in Remus Pharmaceuticals stands at 70.95% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Remus Pharmaceuticals is 5.28% and 0.83% respectively.
The retail shareholding of the Remus Pharmaceuticals is 22.94%.
Changes in shareholding patterns of Remus Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Remus Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Remus Pharmaceuticals Associated Pages
- Remus Pharmaceuticals Share Price
- Remus Pharmaceuticals Share Price chart
- Remus Pharmaceuticals Fundamental Analysis
- Remus Pharmaceuticals Technical Analysis
- Remus Pharmaceuticals Peer Comparison
- Remus Pharmaceuticals Share Price History
- Remus Pharmaceuticals Dividend
- Remus Pharmaceuticals Bonus Share
- Remus Pharmaceuticals Board of Directors
